Cost-effectiveness of warfarin: Trial versus real-world stroke prevention in atrial fibrillation

American Heart Journal

Volumn 157, Issue 6, 2009, Pages 1064-1073

  Sorensen, Sonja V ^a   Dewilde, Sarah ^a   Singer, Daniel E ^b,c   Goldhaber, Samuel Z ^c,d   Monz, Brigitta U ^e   Plumb, Jonathan M ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ARTICLE; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; ECONOMICS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; STROKE; THROMBOSIS;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; HEART DISEASES; HUMANS; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION INHIBITORS; STROKE; THROMBOSIS; WARFARIN;

EID: 67049134013     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.03.022     Document Type: Article

References (54)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. Slot KB, Berge E, Dorman P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008;7640:376-9. (Pubitemid 351300373)
3. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003;22:118-23. (Pubitemid 36302428)
4. Diringer MN, Edwards DF, Mattson DT, et al. Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke 1999;30:724-8. (Pubitemid 29156358)
5. Prevalence of disabilities and associated health conditions among adults\-United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50:120-5.
6. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics\-2006 update: a report from the American Heart Associa-tion Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151.
7. Hart RG, Benavente O, Mc Bride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501. (Pubitemid 29482392)
8. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354.
9. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-52.
10. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6. (Pubitemid 26272308)
11. Samsa GP, Matchar DB, Goldstein LB, etal. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000;160: 967-73. (Pubitemid 30191925)
12. Boulanger L, Kim J, Friedman M, etal. Patterns of useof antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract2006;60: 258-64. (Pubitemid 43337604)
13. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66.
14. Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60. (Pubitemid 38081240)
15. De Schryver EL, van Gijn J, Kappelle LJ, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005;252:1316-21. (Pubitemid 41699020)
16. O'Brien CL, Gage BF. Costs and effective ness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706. (Pubitemid 40216039)
17. Eckman MH, Levine HJ, Salem DN, et al. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effective ness issues. Chest 1998;114(5 Suppl):699S-714S.
18. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effective ness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45. (Pubitemid 26001259)
19. Gage BF, Cardinalli AB, Owens DK. Cost-effective ness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-91. (Pubitemid 28265459)
20. SPORTIF Executive Steering Committee for the SPORTIF V Investiga-tors. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293: 690-8.
21. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):429S-56S. (Pubitemid 39302603)
22. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370: 493-503. (Pubitemid 47212371)
23. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26. (Pubitemid 37087616)
24. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006;54:1231-6. (Pubitemid 44166528)
25. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
26. Gage BF, van Walraven C, Pearce L, etal. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92. (Pubitemid 39407328)
27. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. (Pubitemid 35340540)
28. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4. (Pubitemid 38520629)
29. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest2004;126:1938-45. (Pubitemid 39644002)
30. Yousef ZR, Tandy SC, Tudor V, et al. Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart 2004;90:1259-62. (Pubitemid 39439970)
31. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280: 1690-1. (Pubitemid 28532993)
32. Agency, for Healthcare Researchand Quality (AHRQ). Healthcare Cost & Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) Database]; 2006. Accessed June 21, 2006.
33. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007;120:700-5. (Pubitemid 47176507)
34. Wolf PA, DAgostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22: 312-8.
35. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: howwell do randomized trials translate into clinical practice? JAMA 2003;290:2685-92. (Pubitemid 37475596)
36. Kochanek K, Murphy SL, Anderson RN. National Vital Statistics Reports. Vol. 53, No. 5. Available at: http://www.cdc.gov/nchs/ fastats/pdf/mortality/ nvsr53-05t03.pdf. Last accessed August 31, 2006.
37. Thomson PDR. Red Book for Windows Database]. July; vers 61127. Accessed June 21, 2006.
38. Reed SD, Blough DK, Meyer K, etal. Inpatientcosts, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001;57:305-14. (Pubitemid 32667366)
39. MAG Mutual Healthcare Solutions Inc. Physician's fee and coding guide, Vol 1. Duluth (Ga): MAG Mutual Healthcare Solutions, Inc; 2005. p. 2004.
40. Tung CY, Granger CB, Sloan MA, et al. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasmi-nogen Activator for Occluded Coronary Arteries Study. Circulation 1999;99:370-6. (Pubitemid 29051262)
41. Muntz J, Scott DA, Lloyd A, et al. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int J Technol Assess Health Care 2004;20:405-14. (Pubitemid 39491486)
42. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005;39:446-51. (Pubitemid 40276873)
43. Impact File for IPPS FY. Final Rule. US Department of Health & Human Services Centersfor Medicare&Medicaid Services. Availableat: http: //www.cms.hhs.gov/Acute Inpatient PPS/FFD/list.asp?listpage=2. Last accessed July 15, 2006.
44. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004;10 (14 Suppl):S451-8; discussion S458-61.
45. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26:410-20. (Pubitemid 44050845)
46. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32: 1425-9. (Pubitemid 32530435)
47. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effective ness in health and medicine. New York: Oxford University Press; 1996.
48. Briggs AH. Handling uncertainty in cost-effective ness models. Pharmacoeconomics 2000;17:479-500. (Pubitemid 30398806)
49. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\- Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
50. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005; 36:360-6. (Pubitemid 40170823)
51. Sullivan PW, Arant TW, Ellis SL, et al. The cost effective ness of anticoagulation management services for patients with atrial fibrilla-tion and at high risk of stroke in the US. Pharmacoeconomics 2006; 24:1021-33. (Pubitemid 44497473)
52. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367:404-11. (Pubitemid 43184260)
53. Ng YS, Stein J, Ning M, et al. Comparison of clinical characteristics and functional outcomes of ischemic stroke in different vascular territories. Stroke 2007;38:2309-14. (Pubitemid 47457574)
54. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4. (Pubitemid 26332500)